• TRADE NAME: Nerlynx (Puma)
• INDICATIONS: Early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
  
• CLASS: Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Kinase inhibitor, Tyrosine kinase inhibitor
• HALF-LIFE: 7–17 hours

FDA APPROVAL DATE: 07/17/2017

Aprepitant, Boceprevir, Bosentan, Carbamazepine, Cimetidine, Ciprofloxacin, Clarithromycin, Clotrimazole, Cobicistat, Conivaptan, Crizotinib, Cyclosporine, Dabigatran, Digoxin, Diltiazem, Dronedarone, Efavirenz, Enzalutamide, Erythromycin, Etravirine, Fexofenadine, Fluconazole, Fluvoxamine, Grapefruit Juice, H2-receptor antagonists, Idelalisib, Imatinib, Indinavir, Itraconazole, Ketoconazole, Lansoprazole, Lopinavir, Mitotane, Modafinil, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong or moderate CYP3A4 inhibitors or inducers, Tipranavir, Tofisopam, Troleandomycin, Verapamil, Voriconazole

PREGNANCY CATEGORY: N/A
Can cause fetal harm